Skip to main content

Table 1 Baseline characteristics of patients between first-week iron and third-week iron groups

From: Timing-adjusted iron dosing enhances erythropoiesis-stimulating agent-induced erythropoiesis response and iron utilization

Variables

First-week iron group

Third-week iron group

P value

n = 51

n = 53

Age, years

67.8 ± 10.2

67.6 ± 11.6

0.919

Male, %

60.8

52.8

0.413

Body mass index, kg/m2

21.9 ± 3.6

21.8 ± 3.2

0.815

Hemodialysis vintage, months

94.7 ± 89.0

108.0 ± 75.5

0.158

Single-pool Kt/V

1.05 ± 0.20

1.12 ± 0.24

0.113

Mean CERA dose, μg/4 weeks

129.6 ± 66.9

117.9 ± 68.2

0.344

Arteriovenous fistula, %

96.1

98.1

0.465

Renin-angiotensin system inhibitors, %

49.0

58.5

0.333

Diabetes mellitus, %

35.3

41.5

0.515

Hypertension, %

96.1

98.1

0.485

Cardio vascular disease, %

25.5

24.5

0.910

Hematologic disease, %

5.9

1.9

0.294

Hemoglobin, g/dl

10.7 ± 0.7

10.8 ± 0.9

0.767

Creatinin, mg/dl

11.0 ± 2.2

1.0 ± 2.5

0.906

Blood urea nitrogen, mg/dl

71.6 ± 17.1

72.3 ± 14.6

0.844

Albumin, g/dl

3.85 ± 0.22

3.85 ± 0.31

0.969

C-reactive protein, mg/dl

0.32 ± 0.54

0.22 ± 0.34

0.865

Intact-parathyroid hormon, pg/ml

164.7 ± 78.8

180.1 ± 108.2

0.797

Serum iron, μg/dl

96.4 ± 30.1

89.6 ± 25.9

0.248

Total Iron binding capacity, μg/dl

236.7 ± 34.1

237.1 ± 42.7

0.955

Transferrin saturation, %

40.9 ± 14.2

40.2 ± 14.8

0.826

Ferritin, ng/ml

163.3 ± 63.7

169.6 ± 63.1

0.623

  1. Data are mean ± SD. P values for the difference between the two groups
  2. CERA continuous erythropoietin receptor activator